{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.8","upperLimit":"96.1","value":"92.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"title":"CLL/SLL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.5","upperLimit":"90.2","value":"82.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"WM"}],"denoms":[{"counts":[{"groupId":"OG000","value":"385"}],"units":"Participants"}],"description":"PR or better is defined as the percentage of participants who achieve a partial response or better, as assessed by the investigator. For CLL/SLL, includes PR, nPR, CRi, CR and for WM includes PR, VGPR, and CR. Efficacy results are reported for the B-cell malignancy subtypes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM).","dispersionType":"95% Confidence Interval","groups":[{"description":"The dose regimens from Part 1 (40 mg, 80 mg, 160 mg QD, 160 mg BID and 320 mg QD) and Part 2 (160 mg BID and 320 mg QD) were evaluated in different disease types. Efficacy evaluations are reported by disease type for Parts 1 and 2 combined, as pre-specified in the statistical analysis plan.","id":"OG000","title":"Part 1 and Part 2: Overall"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Set consists of all participants who received at least one dose of zanubrutinib; for WM, participants also must have a baseline IgM (or M-protein) ≥ 5 g/L and no prior exposure to a BTK inhibitor.","reportingStatus":"POSTED","timeFrame":"Up to 6 years and 7 months","title":"Part 1 and Part 2: Partial Response (PR) or Better","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}